- Hardman Research has issued a report on Allergy Therapeutics which highlights the company's continuing gain in market share.

Hardman's report said: 'AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies.

'Pollinex Quattro continues to gain market share despite being available in the EU only on a "Named Patient" basis.

'Investment in marketing over the last three years has been reflected in exceptional growth, with +10% CAGR in sales over the last five years compared to overall allergy vaccine market growth of +1%.

'In fiscal 2017, AGY gained another one-point market share to 13%.

'R&D investment in clinical trials for full approval as a biological in both Europe and the US are progressing with results due to be released in the second half of calendar 2018.'

At 9:16am: [LON:AGY] Allergy Therapeutics PLC share price was +1p at 38.25p

Story provided by